https://www.selleckchem.com/pr....oducts/netarsudil-ar
Of 405 randomized patients, 399 were analyzed (201 in intervention and 198 in control arm). A total of 220 patients (55%) had ID at discharge (i.e., a hepcidin 41μg/l). Primary endpoint was not different (medians (IQR) post-ICU LOS 33(13;9 vs. 33(11;9 days for intervention and control, respectively, median difference - 1(- 3;1) days, p = 0.78). D90 mortality was significantly lower in intervention arm (16(8%) vs 33(16.6%) deaths, absolute risk difference - 8.7 (- 15.1 to - 2.3)%, p = 0.008, OR 95% IC, 0.46, 0.22-0.9
Curtir
Comentario
Compartilhar
